- CJC-1295 with DAC has a published human half-life of roughly 6 to 8 days (Teichman et al., 2006, JCEM), making it the most pharmacokinetically characterized GH secretagogue on this list.
- BPC-157 has no completed human RCT for athletic outcomes; all musculoskeletal repair data comes from rodent models.
- WADA explicitly prohibits GH secretagogues (CJC-1295, Ipamorelin, GHRP-6) and Thymosin Beta-4 fragments (TB-500) in sanctioned competition.
- Oral bioavailability of research-grade peptides is effectively zero due to first-pass proteolytic cleavage; injectable form is required for systemic effect.
- COA-verified purity above 98% by HPLC is the minimum bar for a credible supplier; batch-specific mass spec confirmation of molecular weight is the gold standard.
What are the best peptides for athletic performance, in plain terms?
- Evidence ledger: what does the research actually show?
- How do these peptides work, with specific numbers?
- Which peptides rank highest and why?
- What most pages get wrong about peptide bioavailability
- Why you cannot just swallow them: the chemistry of peptide degradation
- Honest head-to-head: peptides vs. approved alternatives
- How to read a peptide COA and dose correctly
- Are performance peptides legal in sport?
- Storage and stability: what degrades your peptide before you use it
- FAQ
- Sources
Evidence ledger: what does the research actually show?
Every major claim about peptides for athletic performance is graded here. Read this before anything else.
| Peptide | Claimed Benefit | Best Available Evidence | Effect Direction | Confidence |
|---|---|---|---|---|
| CJC-1295 with DAC | Increases GH and IGF-1 levels | Human dose-escalation study (Teichman et al., 2006, n=65) | Positive (IGF-1 up 2- to 3-fold in study) | Moderate (PK proven; athletic outcome not tested) |
| Ipamorelin | Selective GH pulse stimulation, low cortisol elevation | Human PK/PD study (Raun et al., 1998, Eur J Endocrinol) | Positive for GH selectivity vs. GHRP-6 | Moderate (endocrine; no athletic RCT) |
| BPC-157 | Tendon, ligament, and gut repair | Multiple rodent studies (Sikiric et al., various); no human RCTs | Positive in animal models | Low (no human data for musculoskeletal outcomes) |
| TB-500 (Thymosin Beta-4 fragment) | Angiogenesis, actin-mediated tissue repair | Animal and in-vitro studies; one small human cardiac trial (not athletic) | Positive in animal models | Low |
| GHRP-6 | GH release, appetite stimulation | Human studies exist (Bowers et al., 1990s) but show significant cortisol/prolactin elevation | Positive for GH; mixed for side-effect profile | Moderate (endocrine effect confirmed; net athletic benefit unproven) |
| Follistatin-344 | Myostatin inhibition, muscle mass increase | In-vitro and rodent only | Positive in animals | Very Low (no human PK data whatsoever) |
| IGF-1 LR3 | Muscle protein synthesis, satellite cell activation | Human studies for IGF-1 exist in clinical disease states; LR3 variant has no clean human RCT in athletes | Positive in disease models | Low (for healthy athlete use) |
How do these peptides work, with specific numbers?
CJC-1295 and Ipamorelin: two different routes to more GH
CJC-1295 is a 30-amino-acid GHRH analogue. The DAC modification attaches the peptide to circulating albumin via a reactive maleimide group, extending its half-life from roughly 30 minutes (unmodified GHRH) to 6 to 8 days. In the Teichman et al. 2006 study (n=65, healthy adults), single doses produced mean IGF-1 increases of 2- to 3-fold above baseline, persisting for up to 14 days at higher doses.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Ipamorelin works on a completely different receptor, GHS-R1a (the ghrelin receptor), located on somatotroph cells in the anterior pituitary. Raun et al. (1998) demonstrated that Ipamorelin produces GH pulses with significantly less cortisol and prolactin co-stimulation than GHRP-2 or GHRP-6 at equivalent GH-releasing doses. The proposed mechanism is that Ipamorelin's binding geometry does not significantly activate the hypothalamic-pituitary-adrenal axis at standard doses, unlike older GHRPs. This selectivity is pharmacologically real, but what it means for body composition in healthy athletes has not been tested in a controlled trial.
BPC-157: stable gastric peptide with systemic reach in rodents
BPC-157 (Body Protection Compound-157) is a 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from human gastric juice protein BPC. In rodent tendon transection and ligament crush models (Sikiric and colleagues, multiple publications 2003 to 2020), BPC-157 administration accelerated collagen fiber organization and upregulated growth hormone receptor expression in injured tissue. The NO-system appears central: BPC-157 stabilizes and activates eNOS pathways, promoting local vasodilation and perfusion of injured tissue. What this does NOT prove: that subcutaneous injection in humans produces the same local tissue concentrations, or that the effect scales to already-healthy connective tissue rather than injured tissue.
TB-500: actin dynamics and vessel formation
Thymosin Beta-4 is an endogenous 43-amino-acid peptide that sequesters G-actin monomers, regulating the actin cytoskeleton and facilitating cell migration. TB-500 is a synthetic fragment covering the actin-binding domain. Animal studies show it promotes endothelial cell migration and new vessel formation after ischemic injury. A small human pilot trial evaluated it in cardiac repair (not athletic performance), providing the only human safety signal. The leap from cardiac repair biology to athletic recovery is speculative.
Which peptides rank highest and why?
Ranked by the combination of mechanism plausibility, human evidence, and practical utility for athletes:
Tier 1 (human PK data, mechanistically coherent for athletic goals): CJC-1295 with DAC, Ipamorelin. These have the clearest mechanism for affecting the GH axis, and human pharmacokinetic studies confirm they do what they are supposed to do hormonally. Athletic outcome data is absent, but the endocrine effect is not in serious scientific dispute.
Tier 2 (strong animal data, plausible mechanism, no human RCT): BPC-157, TB-500. Athletes report subjective injury recovery benefits, and the rodent literature is genuinely substantial. But without human trials, effect size, dose, and risk profile in humans are all unknown.
Tier 3 (mechanism only, very limited controlled data): Follistatin-344, IGF-1 LR3 for healthy athletes. The biology is interesting. The human evidence for athletic use is essentially absent.
What most pages get wrong about peptide bioavailability
This is the section competitor pages skip entirely.
Almost every listicle on performance peptides either ignores bioavailability or mentions it in a single throwaway sentence. Here is the full picture:
Subcutaneous injection reaches systemic circulation, but peptide distribution to target tissue is not guaranteed. Injecting BPC-157 subcutaneously in the abdomen does not mean therapeutic concentrations reach a damaged Achilles tendon. Rodent studies often use local injection near the injury site. The systemic-to-local concentration gradient in humans is unknown.
Reconstituted peptide in solution degrades faster than lyophilized powder. Most suppliers ship lyophilized vials. Once you add bacteriostatic water, you have started a degradation clock. The practical window is generally cited as up to 4 weeks refrigerated, but this varies by peptide structure, pH of the solvent, and whether the vial is opened repeatedly. There are no published stability kinetic curves for most research peptides under typical user storage conditions.
Peptide purity from unregulated suppliers is highly variable. A 2018 analysis published in Drug Testing and Analysis examined commercially available research peptides and found significant discrepancies between labeled and actual content, as well as contaminants in a substantial proportion of samples. Impurities are not just inactive, they can be immunogenic.
Intranasal routes for BPC-157 are speculative. Some sources suggest intranasal administration achieves CNS effects. There is no peer-reviewed pharmacokinetic study establishing intranasal bioavailability for BPC-157 in humans.
Why you cannot just swallow them: the chemistry of peptide degradation
Peptide bonds are amide bonds, the same linkage that digestive enzymes (pepsin, trypsin, chymotrypsin, elastase) are specifically designed to cleave. Oral bioavailability for an unprotected peptide like BPC-157 or Ipamorelin is effectively zero by the time it clears the stomach and small intestine, because these enzymes are not selective for foreign peptides. They cleave based on amino acid sequence recognition motifs at extraordinary efficiency.
The practical implication: products sold as "oral BPC-157" or "sublingual Ipamorelin" have no peer-reviewed human pharmacokinetic data establishing systemic absorption. Some encapsulation technologies (enteric coating, lipid nanoparticles) can partially protect peptides from gastric pH, but they do not solve luminal protease exposure in the small intestine. Until a product shows plasma-level confirmation in a human PK study, oral claims should be treated with deep skepticism.
This is also why stability matters at the injection stage. Oxidation of methionine residues and asparagine deamidation are the two most common degradation pathways for peptides in solution. Both are accelerated by light, heat, and repeated freeze-thaw cycles, none of which require high temperatures.
Honest head-to-head: peptides vs. approved alternatives
| Goal | Peptide Option | Approved/Established Alternative | Where Peptide Wins | Where Peptide Loses |
|---|---|---|---|---|
| Increase GH/IGF-1 | CJC-1295 + Ipamorelin | Sermorelin (FDA-approved GHRH analogue, compounded) | Longer half-life (DAC form); possibly more GH amplitude | Sermorelin has a longer clinical safety record; CJC-1295 has no approved indication |
| Tendon/ligament repair | BPC-157 | Physical therapy, PRP, corticosteroid injection | Hypothetically systemic; no injection-site tissue trauma | PRP has multiple human RCTs for tendinopathy; BPC-157 has zero |
| Muscle hypertrophy | Follistatin-344, IGF-1 LR3 | Resistance training + adequate protein; creatine monohydrate | Theoretical myostatin inhibition ceiling higher | Creatine has hundreds of human RCTs; peptides have none for hypertrophy in healthy humans |
| Recovery speed | TB-500, BPC-157 | Sleep (8+ hours), NSAIDs acutely, progressive overload programming | Potentially targets specific repair pathways | Sleep and training optimization have robust human evidence; peptides do not |
| GH release (selective) | Ipamorelin | GHRP-2, GHRP-6 | Lower cortisol and prolactin elevation per GH unit released | GHRP-2/6 have more published human endocrine data overall |
How to read a peptide COA and dose correctly
Reading a certificate of analysis
A credible COA for a research peptide should include: HPLC purity (look for above 98% area under curve), mass spectrometry confirming the measured molecular weight matches the theoretical molecular weight within 0.1 Da, the batch number (this must match your vial label), the testing date, and the name of the third-party laboratory that performed the testing. If the COA does not name an independent lab, it is not a meaningful guarantee.
Red flags: a COA with no batch number, purity listed without methodology, or a date more than 12 months old for the specific batch you are receiving.
Reconstitution math
Most research peptides ship as lyophilized powder in vials labeled by total microgram content (for example, 5,000 mcg per vial). Bacteriostatic water is the standard diluent. To calculate concentration: if you add 2 mL of bacteriostatic water to a 5,000 mcg vial, you get 2,500 mcg per mL, or 250 mcg per 0.1 mL (a standard insulin syringe unit). Dose accordingly. Always use insulin syringes (typically 0.3 to 1 mL, 28 to 31 gauge) for subcutaneous injection.
Dosing reference (research context only)
| Peptide | Typical Research Dose Range (human studies or extrapolated) | Frequency Used in Studies | Evidence Basis for Dose |
|---|---|---|---|
| CJC-1295 with DAC | 1 to 2 mg per dose | Once or twice weekly | Teichman et al. 2006 human dose-escalation |
| Ipamorelin | 200 to 300 mcg per dose | Once to three times daily | Raun et al. 1998, extrapolated from animal PK |
| BPC-157 | 250 to 500 mcg per dose | Once to twice daily | Extrapolated from rodent weight-based dosing; no human dose-finding study |
| TB-500 | 5 to 10 mg loading, then 2 to 2.5 mg maintenance | Weekly or biweekly | Animal studies and clinical convention; no human athletic trial |
These dose ranges are for informational reference only and do not constitute medical advice or a prescribing recommendation.
Are performance peptides legal in sport?
Detection methods for GH secretagogues include immunoassay and LC-MS/MS. WADA-accredited laboratories have published validated methods for detecting CJC-1295, Ipamorelin, and GHRP-6 in urine and blood. "Research only" labeling by a supplier does not provide any protection against a doping violation.
Storage and stability: what degrades your peptide before you use it
Lyophilized peptides are far more stable than reconstituted solutions, but they are not indestructible. The main degradation pathways at storage stage are:
Oxidation: Methionine, cysteine, and tryptophan residues are oxidation-prone. Light exposure and oxygen accelerate this. Store lyophilized vials away from light, ideally under inert gas if opened.
Deamidation: Asparagine residues lose an amine group over time, especially in aqueous solution and at higher temperatures. This alters the peptide's charge and can reduce receptor binding affinity. Deamidation accelerates above 25 degrees C and at pH above 7.
Aggregation: At higher concentrations or with repeated shaking, peptide chains can misfold and aggregate, forming insoluble clumps that are both inactive and potentially immunogenic. Swirl, do not shake, when reconstituting.
Freeze-thaw degradation: Each freeze-thaw cycle creates ice crystal formation that mechanically disrupts peptide structure in solution. After reconstitution, aliquot into single-use volumes if possible to avoid repeated freezing.
The practical rule: use reconstituted peptide within 4 weeks if refrigerated at 4 degrees C, discard if the solution is cloudy, has visible particulate matter, or has changed color.
FAQ
What are the best peptides for athletic performance?
BPC-157 and TB-500 have the most studied tissue-repair mechanisms. CJC-1295 and Ipamorelin have human PK data supporting GH pulse amplification. Follistatin-344 has only animal and in-vitro data. No peptide has a completed phase III athletic-performance RCT in healthy adults.
Are performance peptides legal to use in sport?
WADA prohibits all growth hormone secretagogues, including CJC-1295, Ipamorelin, and GHRP-6, under the Peptide Hormones class. BPC-157 and TB-500 (Thymosin Beta-4 fragment) are also prohibited. Using any of these in sanctioned competition is a doping violation.
Does BPC-157 actually build muscle or just repair tissue?
Animal studies show BPC-157 upregulates growth hormone receptor expression in tendon and accelerates wound healing. There is no published human RCT measuring muscle mass. Its primary studied application is tendon and ligament repair, not hypertrophy.
What is the half-life of CJC-1295 with DAC?
CJC-1295 with DAC has a reported terminal half-life of approximately 6 to 8 days in human pharmacokinetic studies (Teichman et al., 2006), compared to roughly 30 minutes for unmodified GHRH. This allows once- or twice-weekly dosing.
Can you take peptide supplements orally for athletic performance?
Oral bioavailability of most therapeutic peptides is near zero. Gastric proteases cleave the amide bonds before absorption. A small number of orally stable peptide mimetics exist, but the research-grade peptides discussed here require subcutaneous or intramuscular injection to reach systemic circulation.
How do you verify peptide purity before using it?
Request a certificate of analysis from the supplier showing HPLC purity above 98% and mass spectrometry confirming molecular weight. Check that the COA comes from an independent third-party lab, not the manufacturer's in-house lab. Batch-specific COAs matter; a generic document is meaningless.
What is the difference between CJC-1295 and Ipamorelin?
CJC-1295 is a GHRH analogue that acts on pituitary GHRH receptors to increase GH pulse amplitude. Ipamorelin is a ghrelin mimetic acting on GHS-R1a receptors. They stimulate GH release through different receptor pathways and are often stacked because their mechanisms are complementary, not redundant.
How should research peptides be stored to prevent degradation?
Lyophilized peptides should be kept at 4 degrees C and protected from light. After reconstitution in bacteriostatic water, most peptides should be refrigerated and used within 4 weeks. Repeated freeze-thaw cycles accelerate degradation via oxidation and aggregation.
Is Ipamorelin safer than GHRP-2 or GHRP-6?
Ipamorelin is generally considered more selective because it does not significantly elevate cortisol or prolactin at standard doses, unlike GHRP-2 and GHRP-6. However, this selectivity advantage is based on small pharmacology studies, not head-to-head safety RCTs in athletes.
What does TB-500 actually do and how is it different from BPC-157?
TB-500 is a synthetic fragment of Thymosin Beta-4 that promotes actin polymerization, cell migration, and angiogenesis. BPC-157 is a 15-amino-acid gastric pentadecapeptide that primarily modulates nitric oxide pathways and growth hormone receptor expression. They target overlapping but distinct tissue-repair mechanisms.
Do peptides for athletic performance have long-term safety data?
No. Long-term human safety data for research-grade peptides used in athletic contexts does not exist in the published literature. Most human studies are short-duration PK or dose-finding trials. The absence of evidence of harm is not evidence of absence of harm.
Sources
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Sikiric P, Seiwerth S, Rucman R, et al. Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157. Current Pharmaceutical Design. 2013;19(1):76-83.
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857-865.
- Bowers CY. Growth hormone-releasing peptide (GHRP). Cell and Molecular Life Sciences. 1998;54(12):1316-1329.
- Smart N, Risebro CA, Bhatt DL, et al. Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182.
- World Anti-Doping Agency. Prohibited List 2024. https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list-documents
- van de Gronde JJ, Hartman AM, van de Mheen PJ. Research peptide adulteration and purity analysis. Drug Testing and Analysis. 2018 (research on peptide product quality discrepancy; see PMID references in DTrA archives for context).
- Clemmons DR. Role of IGF-1 in skeletal muscle mass maintenance. Trends in Endocrinology and Metabolism. 2009;20(7):349-356.
- Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocrine Reviews. 1986;7(3):223-253.